ERBB2 and breast carcinoma: It was identified that silencing of miR-193a-3p through hypermethylation can promote HER2 positive breast cancer progress by targeting growth factor receptor bound protein 7 (GRB7), extracellular signal-regulated kinase 1/2 (ERK1/2), and forkhead box M1 (FOXM1) signaling [41].